Canran Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Canran Lv has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chu Chen
Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital Yichang, 443000 Yichang, Hubei, China
1 shared publication - Cuiyuan Huang
Hubei Key Laboratory of Ischemic Cardiovascular Disease, 443000 Yichang, Hubei, China
1 shared publication - Jian Yang
Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, China
1 shared publication - Jing Zhang
Hubei Key Laboratory of Ischemic Cardiovascular Disease, 443000 Yichang, Hubei, China
1 shared publication - Le Zhang
Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Li Liu
Hubei Key Laboratory of Ischemic Cardiovascular Disease, 443000 Yichang, Hubei, China
1 shared publication
Latest Publications
- Open Access
- 13 November 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (11)
Endothelial Dysfunction in Sex-Specific Disparities in Cardiovascular Diseases: Biological Mechanisms, Diagnostic-Therapeutic Differences, and Translational Medicine Strategies
Sex-specific disparities in the pathogenesis and outcomes of cardiovascular diseases (CVDs) highlight critical gaps in current clinical paradigms, particularly regarding endothelial dysfunction as a pivotal mediator of such differences. Males have a higher incidence of atherosclerosis-related CVD, while postmenopausal females experience microvascular dysfunction due to estrogen loss and androgen dominance. Estrogen confers cardioprotective effects via nitric oxide (NO)-mediated vasodilation and antioxidant pathways. In contrast, androgens exert dual pathological effects by promoting inflammation and oxidative stress in a concentration-dependent manner. Clinically, men develop obstructive coronary disease, whereas women present with underdiagnosed microvascular ischemia due to sex-neutral thresholds. Sex-specific risks (e.g., smoking/diabetes in women) and treatment disparities persist in CVDs, meaning sex-stratified diagnostics/therapeutics and trial reforms are needed to advance precision cardiology. Unlike traditional reviews that focus on mechanisms, this study aims to link molecular insights with translational strategies by proposing endothelial-targeted therapies, sex-adjusted diagnostic algorithms, and policy-driven trial reforms. By prioritizing the endothelial–sex hormone crosstalk as the nexus of pathophysiology and clinical translation, this synthesis advances precision cardiology beyond conventional symptom-focused paradigms.
- 13 November 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (11)
Open AccessEndothelial Dysfunction in Sex-Specific Disparities in Cardiovascular Diseases: Biological Mechanisms, Diagnostic-Therapeutic Differences, and Translational Medicine Strategies
Sex-specific disparities in the pathogenesis and outcomes of cardiovascular diseases (CVDs) highlight critical gaps in current clinical paradigms, particularly regarding endothelial dysfunction as a pivotal mediator of such differences. Males have a higher incidence of atherosclerosis-related CVD, while postmenopausal females experience microvascular dysfunction due to estrogen loss and androgen dominance. Estrogen confers cardioprotective effects via nitric oxide (NO)-mediated vasodilation and antioxidant pathways. In contrast, androgens exert dual pathological effects by promoting inflammation and oxidative stress in a concentration-dependent manner. Clinically, men develop obstructive coronary disease, whereas women present with underdiagnosed microvascular ischemia due to sex-neutral thresholds. Sex-specific risks (e.g., smoking/diabetes in women) and treatment disparities persist in CVDs, meaning sex-stratified diagnostics/therapeutics and trial reforms are needed to advance precision cardiology. Unlike traditional reviews that focus on mechanisms, this study aims to link molecular insights with translational strategies by proposing endothelial-targeted therapies, sex-adjusted diagnostic algorithms, and policy-driven trial reforms. By prioritizing the endothelial–sex hormone crosstalk as the nexus of pathophysiology and clinical translation, this synthesis advances precision cardiology beyond conventional symptom-focused paradigms.